The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The price of Immuneering Corp (NASDAQ: IMRX) closed at $6.08 in the last session, down -1.94% from day before closing price of $6.2. In other words, the price has decreased by -$1.94 from its previous closing price. On the day, 0.55 million shares were traded. IMRX stock price reached its highest trading level at $6.4 during the session, while it also had its lowest trading level at $6.07.
Ratios:
We take a closer look at IMRX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 24.00 and its Current Ratio is at 24.00. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In the most recent recommendation for this company, Leerink Partners on October 31, 2025, initiated with a Outperform rating and assigned the stock a target price of $15.
Needham reiterated its Buy rating for the stock on March 15, 2024, while the target price for the stock was revised from $20 to $15.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 03 ’25 when Feinberg Peter bought 7,500 shares for $6.67 per share. The transaction valued at 50,025 led to the insider holds 156,766 shares of the business.
Morales Mallory bought 300 shares of IMRX for $1,917 on Oct 01 ’25. The Chief Accounting Officer now owns 27,533 shares after completing the transaction at $6.39 per share. On Oct 01 ’25, another insider, Neufeld Leah R, who serves as the CHIEF PEOPLE OFFICER of the company, bought 800 shares for $6.38 each. As a result, the insider paid 5,103 and bolstered with 23,344 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IMRX now has a Market Capitalization of 392585408 and an Enterprise Value of 168938656.
Stock Price History:
The Beta on a monthly basis for IMRX is 0.46, which has changed by 2.583815 over the last 52 weeks, in comparison to a change of 0.13613915 over the same period for the S&P500. Over the past 52 weeks, IMRX has reached a high of $10.08, while it has fallen to a 52-week low of $1.10. The 50-Day Moving Average of the stock is -6.13%, while the 200-Day Moving Average is calculated to be 50.07%.
Shares Statistics:
According to the various share statistics, IMRX traded on average about 1.87M shares per day over the past 3-months and 756390 shares per day over the past 10 days. A total of 63.48M shares are outstanding, with a floating share count of 48.82M. Insiders hold about 26.02% of the company’s shares, while institutions hold 41.88% stake in the company. Shares short for IMRX as of 1764288000 were 7289153 with a Short Ratio of 3.90, compared to 1761868800 on 7719578. Therefore, it implies a Short% of Shares Outstanding of 7289153 and a Short% of Float of 13.0.
Earnings Estimates
Currently, 6.0 analysts are dedicated to thoroughly evaluating and rating the performance of Immuneering Corp (IMRX) in the stock market.The consensus estimate for the next quarter is -$0.35, with high estimates of -$0.35 and low estimates of -$0.35.
Analysts are recommending an EPS of between -$1.29 and -$1.56 for the fiscal current year, implying an average EPS of -$1.42. EPS for the following year is -$1.6, with 6.0 analysts recommending between -$1.12 and -$2.26.
